Cavit Boz

Cavit Boz

Auto-generated profile, based on publicly available information

Cavit Boz

Department of Neurology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2006 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
CBCavit Boz
Cavit Boz
MOMehmet Ozmenoglu
Mehmet Ozmenoglu
SVSibel Velioglu
Sibel Velioglu
KKKagan Kilinc
Kagan Kilinc
AOAsim Orem
Asim Orem
VAVildan Altunayoglu
Vildan Altunayoglu

11 October 2004 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Open access
PDF file
CBCavit Boz
Cavit Boz
SVSibel Velioglu
Sibel Velioglu
MOMehmet Ozmenoglu
Mehmet Ozmenoglu
KSKemal Sayar
Kemal Sayar
ZAZekeriya Alioglu
Zekeriya Alioglu
MTMurat Topbas
Murat Topbas
Abstract  The aim of this present study was to evaluate the temperament and character profiles of persons with tension‐type headache (TTH) and migraine, and to compare the results with those of healthy controls. The study population consisted of 81 patients with TTH (60 female, 21 male) and 56 patients with migraine (34 female, 17 male) aged 18–50 years, according to the criteria of the International Headache Society with age and gender – matched healthy control subjects (54 female, 28 male). All participants were instructed to complete a self‐administered 240‐item temperament and character inventory (TCI) questionnaire and Beck Depression Inventory (BDI). The TCI assesses four dimensions of temperament, namely, novelty seeking (NS), harm avoidance (HA), reward dependence (RD), and persistence (P), and three dimensions of character, being self‐directedness (SD), cooperativeness (C) and self‐transcendence (ST). According to the TCI biosocial model, the temperament dimension HA is suggested to indicate central serotonergic turnover, which is further correlated with depressive state. It was found that mean BDI scores were significantly higher in patients with TTH and migraine than in those of the controls. The BDI scores were positively correlated with HA scores (r = 0.295, P < 0.001) and negatively correlated with SD (r = −0.386, P < 0.001) and C scores (r = −0.164, P= 0.016). Multivariate analysis showed that BDI scores had significant covariation for HA, SD and C. Despite using the BDI score as a covariate, TTH patients had higher HA scores (P = 0.01) than did the control subjects. No significant differences were found between the groups regarding main NS, RD, P, SD, C and ST scores. Based on the main results of this study, it is suggested that higher serotonergic activity related to HA scores in TTH patients and their relationship with depressive symptomatology supports the role of central serotonergic involvement in TTH.

26 June 2017 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
CBCavit Boz
Cavit Boz
MTMurat Terzi
Murat Terzi
SKSerap Zengin Karahan
Serap Zengin Karahan
SSSedat Sen
Sedat Sen
YSYasemin Sarac
Yasemin Sarac
MMMurat Emrah Mavis
Murat Emrah Mavis
Background: Women with multiple sclerosis (MS) experience an increased risk of relapse in the postpartum period. High-dose methylprednisolone is the first-line treatment for acute relapses. Objectives: To determine the transfer of methylprednisolone into human milk in breastfeeding MS patients. Methods: Methylprednisolone therapy was given for postpartum relapse to nine patients for three consecutive days, and seven patients received a daily infusion once a month. Breast milk samples were obtained before infusion and 1, 2, 4, 8, and 12 hours after completion of infusion. Results: Methylprednisolone concentrations in milk were below detection limits immediately before infusion. Cmax was measured at 1, 2, 4, 8, and 12 hours after infusion and levels of 2.100, 1.659, 0.680, 0.174, and 0.102 µg/mL were determined, respectively. The absolute infant dose was 98.98 µg/kg/day, and the relative infant dose (RID) was 0.71% of the weight-adjusted maternal dose. Conclusion: The level of methylprednisolone transfer into breast milk is very low. The RID for methylprednisolone was lower than the generally accepted value. As methylprednisolone therapy is of short duration, infant exposure would be very low should a mother choose to breastfeed 1 hour after infusion. Waiting 2–4 hours after infusion will limit infant exposure still further.

31 August 2021 in Neurology
Verified
Journal Article
Open access
PDF file
IRIzanne Roos
Izanne Roos
ELEmmanuelle Leray
Emmanuelle Leray
RCRomain Casey
Romain Casey
DHDana Horakova
Dana Horakova
EHEva Kubala Havrdová
Eva Kubala Havrdová
TGthe MSBase and OFSEP Study Groups
the MSBase and OFSEP Study Groups
Objective: To compare the clinical effectiveness of high- and low-efficacy treatments in patients with recently active and inactive secondary progressive multiple sclerosis (SPMS) after accounting for therapeutic lag. Methods: Patients treated with high- (natalizumab, alemtuzumab, mitoxantrone, ocrelizumab, rituximab, cladribine, fingolimod) or low-efficacy (interferon β, glatiramer acetate, teriflunomide) therapies after SPMS onset were selected from MSBase and OFSEP, two large observational cohorts. Therapeutic lag was estimated for each patient based on their demographic and clinical characteristics. Propensity score was used to match patients treated with high and low-efficacy therapies. Outcomes after disregarding the period of therapeutic lag were compared in paired, pairwise-censored analyses. Results: 1000 patients were included in the primary analysis. Patients with active SPMS treated with high-efficacy therapy experienced less frequent relapses than those on low-efficacy therapy (hazard ratio [HR] 0.7, p=0.006). In patients with inactive SPMS, there was no evidence for a difference in relapse frequency between groups (HR=0.8,p=0.39). No evidence for a difference in the risk of disability progression was observed. Conclusion: In treated patients with SPMS, high-efficacy therapy is superior to low-efficacy therapy in reducing relapses in patients with active, but not those with inactive, SPMS. However, more potent therapies do not offer an advantage in reducing disability progression in this patient group. Classification of Evidence: This study provides class III evidence that high-efficacy therapy is superior to low-efficacy therapy in reducing relapses in patients with active SPMS whilst we did not find a difference in disability progression between patients treated with high- and low-efficacy therapy.

24 December 2024 in Neurology
Verified
Journal Article
Closed access
PSPakeeran Siriratnam
Pakeeran Siriratnam
SHSaif Huda
Saif Huda
AWAnneke Van der Walt
Anneke Van der Walt
PSPaul G. Sanfilippo
Paul G. Sanfilippo
SSSifat Sharmin
Sifat Sharmin
FMFor Msbase
For Msbase
In aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), disability accrual is mostly attributed to relapses. This study aimed to assess the prevalence of progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) in AQP4-IgG NMOSD. This was a retrospective cohort study of patients with AQP4-IgG NMOSD enrolled in the MSBase international data registry. Patients required a minimum of 3 recorded Expanded Disability Status Scale (EDSS) scores: baseline, event, and a 6-month confirmation score. Presence and absence of relapses between the baseline and event EDSS scores determined RAW and PIRA, respectively. Descriptive statistics were used to present the results. A total of 181 patients followed for a median of 4.5 years (Q1 1.7, Q3 7.8) were included. Most patients were female (88.4%), and the median age at disease onset was 38.1 years. Overall, 4 patients (2.2%) developed 5 incidences of PIRA and 13 patients developed RAW (7.2%). This multicenter study highlights that PIRA is very rare in AQP4-IgG NMOSD. Limitations of this study include the sole focus of overall EDSS to measure disability, lack of requirement for a second EDSS score to confirm baseline EDSS, and the absence of magnetic resonance imaging information for all patients.

14 September 2007 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Closed access
PDF file
CBCavit Boz
Cavit Boz
SGSibel Gazioglu
Sibel Gazioglu
VAVildan Altunayoglu
Vildan Altunayoglu
CHCicek Hocaoglu
Cicek Hocaoglu